Natural Product (NP) Details

General Information of the NP (ID: NP7913)
Name
Penciclovir
Synonyms
penciclovir; 39809-25-1; Denavir; Penciclovirum; Vectavir; Penciclovirum [INN-Latin]; BRL 39123; BRL-39123; Pencyclovir; 9-(4-Hydroxy-3-(hydroxymethyl)butyl)guanine; 2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-3H-purin-6-one; Penciceovir; UNII-359HUE8FJC; 9-(4-HYDROXY-3-(HYDROXYMETHYL)BUT-1-YL)GUANINE; PE2; C10H15N5O3; 9-(4-hydroxy-3-hydroxymethylbut-1-yl)-guanine; 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine; 2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-3,9-dihydropurin-6-one; 359HUE8FJC; CHEMBL1540; CHEBI:7956; 9-[4-Hydroxy-3-(hydroxymethyl)butyl]guanine; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-(4-hydroxy-3-(hydroxymethyl)butyl)-; 9-[2-hydroxy-1-(hydroxymethyl)-ethoxymethyl]guanine; NCGC00164630-01; 2-amino-9-(4-hydroxy-3-(hydroxymethyl)butyl)-1H-purin-6(9H)-one; 2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-1,9-dihydro-6H-purin-6-one; DSSTox_CID_26491; DSSTox_RID_81662; DSSTox_GSID_46491; PCV; Penciclovir [USAN:INN:BAN]; Adenovir; 2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-1H-purin-6-one; 2-amino-9-(4-hydroxy-3-(hydroxymethyl)butyl)-1,9-dihydro-6H-purin-6-one; SMR000466317; Denavir (TN); CAS-39809-25-1; CCRIS 9213; SR-05000001512; 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine; Penciclovir (USAN/INN); HSDB 8123; Penciclovir,(S); 2-Amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)butyl]-6H-purin-6-one; MB2488; SCHEMBL3494; Penciclovir-d4 (deuterated); MLS000759422; MLS001424110; ZINC1899; DTXSID9046491; SCHEMBL19236307; HMS2051D06; HMS2090H11; HMS2232A11; HMS3371P04; HMS3393D06; HMS3652H07; HMS3713P14; Pharmakon1600-01502320; BCP13112; Tox21_112248; 2-amino-9-(4-hydroxy-3-(hydroxymethyl)butyl)-3H-purin-6(9H)-one; BDBM50210804; MFCD00866931; NSC759624; s4184; AKOS007930676; AKOS026750166; BRL 39123;VSA 671; Tox21_112248_1; AC-8067; CCG-101000; CCG-213029; CCG-266987; CS-1355; DB00299; KS-5016; NC00250; NSC 759624; NSC-759624; NCGC00263533-01; NCGC00386270-02; AK546699; HY-17424; FT-0601627; FT-0673555; P2164; SW197630-2; C07417; D05407; J90026; W-5154; AB00698242-05; AB01275514-01; AB01275514_02; AB01566918_01; 809P251; A824740; Q420364; SR-01000763121; SR-01000763121-3; SR-05000001512-1; SR-05000001512-2; 2-[2-(2-Amino-6-hydroxy-purin-9-yl)-ethyl]-propane-1,3-diol; 2-azanyl-9-[3-(hydroxymethyl)-4-oxidanyl-butyl]-3H-purin-6-one; 2-Amino-9-(4-hydroxy-3-hydroxymethyl-butyl)-1,9-dihydro-purin-6-one; 2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-6,9-dihydro-3H-purin-6-one; 2-Amino-9-(4-hydroxy-3-hydroxymethyl-butyl)-1,9-dihydro-purin-6-one (PCV); 2-Amino-9-(4-hydroxy-3-hydroxymethyl-butyl)-1,9-dihydro-purin-6-one(PCV, Penciclovir)
    Click to Show/Hide
Species Origin Homo sapiens ...     Click to Show/Hide
Homo sapiens
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Disease Human immunodeficiency virus disease [ICD-11: 1C62] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absporption
Caco-2 Permeability
 -5.654
 
MDCK Permeability
 -4.883
 
PAMPA
 ++
 
HIA
 +++
 
Distribution
VDss
 0.064
 
PPB
 19%
 
BBB
 +++
 
Metabolism
CYP1A2 inhibitor
 - - -
CYP1A2 substrate
 - - -
CYP2C19 inhibitor
 - - -
CYP2C19 substrate
 - - -
CYP2C9 inhibitor
 - - -
CYP2C9 substrate
 -
CYP2D6 inhibitor
 - - -
CYP2D6 substrate
 - -
CYP3A4 inhibitor
 - - -
CYP3A4 substrate
 - - -
CYP2B6 inhibitor
 - - -
CYP2B6 substrate
 - - -
CYP2C8 inhibitor
 - - -
HLM Stability
 - -
 
Excretion
CLplasma
 9.021
 
T1/2
 2.104
Toxicity
DILI
 +++
 
Rat Oral Acute Toxicity
 - - -
 
FDAMDD
 - - -
 
Respiratory
 - - -
 
Human Hepatotoxicity
 +++
 
Ototoxicity
 +++
 
Drug-induced Nephrotoxicity
 ++
 
Drug-induced Neurotoxicity
 +++
 
Hematotoxicity
 ++
 
Genotoxicity
 +++
 
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++). 2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C10H15N5O3
PubChem CID
135398748
Canonical SMILES
C1=NC2=C(N1CCC(CO)CO)N=C(NC2=O)N
InChI
1S/C10H15N5O3/c11-10-13-8-7(9(18)14-10)12-5-15(8)2-1-6(3-16)4-17/h5-6,16-17H,1-4H2,(H3,11,13,14,18)
InChIKey
JNTOCHDNEULJHD-UHFFFAOYSA-N
CAS Number
CAS 39809-25-1
ChEBI ID
CHEBI:7956
TTD Drug ID
D07BYK
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          lamivudine      Hepatitis virus infection     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model Huh-7 CVCL_0336 Adult hepatocellular carcinoma Homo sapiens
                    Experimental
                    Result(s)		 These results suggest that combinations of 3TC and PCV may act synergistically against HBV in vivo.
Target and Pathway
Target(s) Herpes simplex virus DNA polymerase UL30 (HSV UL30)  Molecule Info  [3]
Thymidine kinase 1 (TK1)  Molecule Info  [4]
References
Reference 1 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
Reference 2 Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology. 1997 Jul;26(1):216-25.
Reference 3 Antimicrobial strategies: inhibition of viral polymerases by 3'-hydroxyl nucleosides. Drugs. 2009;69(2):151-66.
Reference 4 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
 Download Picture         KEGG Link